IndustryCompany release

InMed completes Mentari merger and renames itself Mentari Therapeutics, with PACAP migraine antibody in Phase 1

🇺🇸 InMed Pharmaceuticals Inc. (INM) · Mon 16 Nov 2026

InMed Pharmaceuticals closed its two-step merger with Mentari Therapeutics on 6 November and adopted the Mentari name; lead anti-PACAP antibody MT-001 is in a New Zealand Phase 1 trial.

InMed Pharmaceuticals Inc. has completed its two-step merger with Mentari Therapeutics and changed its name to Mentari Therapeutics, Inc. The transaction closed on 6 November 2026, according to the management's discussion and analysis (MD&A) filed alongside the company's Form 8-K.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): InMed Pharmaceuticals Inc. ↗

Article written by VigiEye from the official source (InMed Pharmaceuticals Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →